


What is claimed is:

CLAIMS

1. A compound having the structural formula (VII):



wherein

R^1 is selected from hydrogen, C_1 - C_6 unsubstituted alkyl, OR' , $COOR'$ and $CONR'R''$;
each R^3 is independently selected from hydrogen, C_1 - C_6 unsubstituted alkyl, OR' , $COOR'$ and $CONR'R''$;

R^4 is a group selected from hydrogen, halogen, CN, C_1 - C_6 unsubstituted alkyl, OR' , and NHR' ;

R^5 is R^x or NR^xR^y , wherein each of R^x and R^y is independently selected from H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl and R^x and R^y may together form a 3- to 7-membered ring, and each of R^x and R^y is optionally substituted with one or more of halogen, CN, OR' , $NR'R''$, alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl and alkoxyalkyl; *provided that* when R^5 is R^x , R^x is not H;


each R_L is independently $(CH_2)_m$ and m is 1;

each R' and R'' is independently selected from hydrogen and C_1 - C_6 unsubstituted alkyl and R' and R'' may together form a 3- to 7-membered ring; and

n is 1 or 2,

or a pharmaceutically acceptable salt thereof.


2. The compound of claim 1, wherein R^4 is H.
3. The compound of claim 1 or 2, wherein R^1 is H.
4. The compound of claim 1, having the structural formula (X):




5. The compound of any of claims 1-4, wherein R^5 is R^x .
6. The compound of claim 5, wherein R^x is a linear or branched C_1 - C_6 alkyl.
7. The compound of claim 6, wherein R^x is a linear or branched C_2 - C_4 alkyl.
8. The compound of claim 7, wherein R^x is n-propyl or isopropyl.
9. The compound of any of claims 1-4, wherein R^5 is NR^xR^y .
10. The compound of claim 9, wherein one of R^x and R^y is H.
11. The compound of claim 9, wherein the R^x and R^y together, along with the N in NR^xR^y , form a 3- to 5-membered heterocyclic group, optionally substituted with one or more of halogen, CN, OR', $\text{NR}'\text{R}''$, alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl and alkoxyalkyl.


12. The compound of claim 11, wherein the heterocyclic group is a 4-membered heterocyclic group.


13. The compound of any of claims 1-12, selected from the group consisting of:





14. The compound of claim 13, selected from





15. A pharmaceutical composition comprising a compound according to any of claims 1-14, and a pharmaceutically acceptable excipient, carrier, or diluent.
16. The pharmaceutical composition of claim 15, wherein the composition is suitable for oral administration.
17. A unit dosage form comprising a pharmaceutical composition according to claim 15 or 16.
18. The unit dosage form of claim 17, wherein the dosage form is a tablet or a capsule.
19. A pharmaceutical composition comprising a compound according to any one of claims 1-14 for treating one or more of cancer or inflammatory or immune-mediated diseases or disorders selected from asthma, allergies, arthritis, juvenile arthritis, inflammatory bowel diseases, endocrinopathies, neurodegenerative diseases, autistic spectrum disorder, depression, Alzheimer's disease, Guillain-Barre syndrome, obsessive-compulsive disorder, optic neuritis, retinal degeneration, dry eye syndrome (DES), Sjogren's syndrome, amyotrophic lateral

sclerosis (ALS), Parkinson's disease, Huntington's Disease, Guillain-Barre syndrome, myasthenia gravis, and chronic idiopathic demyelinating disease (CID), vascular diseases, skin diseases, Hashimoto's thyroiditis, pernicious anemia, Cushing's disease, Addison's disease, chronic active hepatitis, polycystic ovary syndrome (PCOS), celiac disease, pemphigus, transplant rejection and graft-versus-host disease (GVDH).

20. A pharmaceutical composition comprising a compound according to any one of claims 1-14 for treating one or more of cancer or inflammatory or immune-mediated diseases or disorders selected from: asthma, allergies, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile arthritis, ulcerative colitis, Crohn's disease, type 1 diabetes, Graves' disease, multiple sclerosis (MS), autistic spectrum disorder, depression, Alzheimer's disease, Guillain-Barre syndrome, obsessive-compulsive disorder, optic neuritis, retinal degeneration, dry eye syndrome (DES), Sjogren's syndrome, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Huntington's Disease, Guillain-Barre syndrome, myasthenia gravis, chronic idiopathic demyelinating disease (CID), autoimmune hearing loss, systemic vasculitis, atherosclerosis, acne vulgaris, dermatomyositis, pemphigus, systemic lupus erythematosus (SLE), discoid lupus erythematosus, scleroderma, psoriasis, plaque psoriasis, vasculitis, vitiligo, alopecias, Hashimoto's thyroiditis, pernicious anemia, Cushing's disease, Addison's disease, chronic active hepatitis, polycystic ovary syndrome (PCOS), celiac disease, allograft transplant rejection and graft-versus-host disease (GVDH).
21. The pharmaceutical composition of claim 19, wherein the composition is for treating one or more disease or disorder selected from: asthma, allergies, arthritis, juvenile arthritis, inflammatory bowel diseases, endocrinopathies, neurodegenerative diseases, autistic spectrum disorder, depression, Alzheimer's disease, Guillain-Barre syndrome, obsessive-compulsive disorder, optic neuritis, retinal degeneration, dry eye syndrome (DES), Sjogren's syndrome, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Huntington's Disease, Guillain-Barre syndrome, myasthenia gravis, and chronic idiopathic demyelinating disease (CID), vascular diseases, skin diseases, Hashimoto's thyroiditis, pernicious anemia, Cushing's disease, Addison's disease, chronic active hepatitis, polycystic ovary syndrome (PCOS), celiac disease, pemphigus, transplant rejection, graft-versus-host disease (GVDH), or a related disease or disorder thereof.
22. The pharmaceutical composition of claim 20, wherein the composition is for treating one or more disease or disorder selected from: asthma, allergies, rheumatoid arthritis, psoriatic arthritis,

ankylosing spondylitis, juvenile arthritis, ulcerative colitis, Crohn's disease, type 1 diabetes, Graves' disease, multiple sclerosis (MS), autistic spectrum disorder, depression, Alzheimer's disease, Guillain-Barre syndrome, obsessive-compulsive disorder, optic neuritis, retinal degeneration, dry eye syndrome (DES), Sjogren's syndrome, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Huntington's Disease, Guillain-Barre syndrome, myasthenia gravis, chronic idiopathic demyelinating disease (CID), autoimmune hearing loss, systemic vasculitis, atherosclerosis, acne vulgaris, dermatomyositis, pemphigus, systemic lupus erythematosus (SLE), discoid lupus erythematosus, scleroderma, psoriasis, plaque psoriasis, vasculitis, vitiligo, alopecias, Hashimoto's thyroiditis, pernicious anemia, Cushing's disease, Addison's disease, chronic active hepatitis, polycystic ovary syndrome (PCOS), celiac disease, allograft transplant rejection, graft-versus-host disease (GVHD), or a related disease or disorder thereof.

23. The pharmaceutical composition of claim 19, wherein the composition is for treating cancer.
24. The pharmaceutical composition of claim 20, wherein the disease or disorder is one or more of rheumatoid arthritis, ankylosing spondylitis, psoriasis, atopic dermatitis, inflammatory bowel disease, Crohn's, ulcerative colitis, DES, vitiligo, alopecia areata and alopecia totalis.